Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03287947 · ClinicalTrials.gov registry record · Phase 2
LCI-GI-APX-NIN-001: Nintedanib in Metastatic Appendiceal Carcinoma
A Phase 2 study, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT03287947 is a Phase 2 study that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 5 participants.
The verdict
NCT03287947, a Phase 2 study, was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this trial is to evaluate the disease control rate of nintedanib in subjects with metastatic appendiceal cancer for whom initial fluoropyrimidine-based chemotherapy has failed. Based on previous studies, the anticancer activity of nintedanib in lung and ovarian cancer trials, along with the similarities between appendiceal and colorectal cancer and potentially ovarian cancer, warrant additional investigation for the optimal treatment of metastatic appendiceal carcinomas.
Interventions
- DRUG nintedanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2017-11-10 |
| Est. Completion | 2019-10-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03287947
The ClinicalTrials.gov registry entry for NCT03287947 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which nintedanib is the first listed.
NCT03287947 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03287947 about?
NCT03287947 is a clinical study titled "LCI-GI-APX-NIN-001: Nintedanib in Metastatic Appendiceal Carcinoma". The purpose of this trial is to evaluate the disease control rate of nintedanib in subjects with metastatic appendiceal cancer for whom initial fluoropyrimidine-based chemotherapy has failed. Based on previous studies, the anticancer activity of nintedanib in lung and ovarian cancer trials, along wi...
What is the current status of trial NCT03287947?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2017-11-10. Estimated completion is 2019-10-27.
What interventions are being tested in trial NCT03287947?
The interventions under investigation include: nintedanib (DRUG).
Who is sponsoring clinical trial NCT03287947?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.